Compare GSK plc (GSK) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs NEOS S&P 500 High Income ETF — how do they compare? GSK plc trades at $52.8 (market cap $101.34B), while NEOS S&P 500 High Income ETF trades at $53.54. The key difference: GSK plc pays a 3.49% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | SPYI | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $54.07 |
52-Week Low | $36.20 | $47.98 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
SPYI trades at $53.66, up 0.19% today, with a bullish technical signal from moving averages. The ETF has surpassed $10 billion in assets under management as of June 2026, driven by strong inflows. Recent dividends include $0.52-$0.54 per share, supporting its high-income appeal. The fund's covered-call strategy aims to deliver monthly distributions while retaining partial upside.
Outlook remains positive due to robust investor demand for income solutions, though risks include potential return of capital and fee impact. The ETF's 12% yield attracts retirees, but tax implications and market volatility require careful consideration. Competition with JEPI highlights the need for strategy differentiation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
